| Literature DB >> 30150467 |
Alan E Gross1,2, Hongmei Xu3, Diansong Zhou3, Nidal Al-Huniti3.
Abstract
The manufacturer-recommended aztreonam dosing for patients with creatinine clearance values of <10 ml/min/1.73 m2 is complex. It is not known whether simpler posthemodialysis dosing administered once daily or thrice weekly can reliably achieve pharmacodynamic goals. We found that 1 or 2 g administered once daily after hemodialysis had >90% probability of target attainment up to MICs of 4 or 8 mg/liter, respectively. Thrice-weekly dosing should generally be avoided, except in nonsevere infections with MICs of ≤0.5 mg/liter.Entities:
Keywords: Monte Carlo simulation; aztreonam; end-stage renal disease; kidney dysfunction; pharmacodynamics; renal failure
Mesh:
Substances:
Year: 2018 PMID: 30150467 PMCID: PMC6201116 DOI: 10.1128/AAC.01066-18
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191